🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

49 results for “Turn” Clear

  1. ALXN 2040, ALXN 2040

    Alexion Europe SAS

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule active

    1 trial

  2. APL-2

    Apellis Europe B.V.

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule completed

    1 trial

  3. Cemdisiran

    Regeneron UK Limited

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule terminated

    1 trial

  4. Cemdisiran, Pozelimab

    Lacuna Pharma Pty Ltd

    Paroxysmal nocturnal hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  5. Crovalimab

    Hoffmann-La Roche

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule active

    1 trial

  6. Crovalimab, ECULIZUMAB, Crovalimab

    Hoffmann-La Roche

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  7. Danicopan

    Alexion Europe SAS

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule active

    1 trial

  8. ECULIZUMAB, Crovalimab, Crovalimab

    Hoffmann-La Roche

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  9. IPTACOPAN HYDROCHLORIDE

    Novartis Pharmaceuticals

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  10. IPTACOPAN, LNP023

    Novartis Pharmaceuticals

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  11. Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Norditropin FlexPro, injektionsvæske, opløsning i fyldt pen, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin

    Ascendis Pharma Endocrinology Division A/S

    Turner Syndrome (TS), idiopathic short stature (ISS), short stature homeobox containing gene deficiency (SHOX-D), small for gestational age (SGA)

    phase 3 small molecule active

    1 trial

  12. MiLES

    Turn Therapeutics

    Cancer

    phase 3 other active

    1 trial

  13. Norditropin FlexPro, injektionsvæske, opløsning i fyldt pen, Sogroya 10 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 15 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 5 mg/1.5 mL solution for injection in pre-filled pen

    NovoThirteen

    Children with short stature either born small for gestational age or with Turner syndrome, Noonan syndrome, or idiopathic short stature

    phase 3 small molecule active

    1 trial

  14. Pegcetacoplan

    Apellis Europe B.V.

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule completed

    2 trials

  15. Pozelimab

    Regeneron UK Limited

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule active

    4 trials

  16. Pozelimab, Cemdisiran

    Lacuna Pharma Pty Ltd

    Paroxysmal nocturnal hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  17. REGN3918

    Regeneron UK Limited

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule terminated

    1 trial

  18. Ravulizumab

    Regeneron UK Limited

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule active

    1 trial

  19. Simvastatina NORMON 10 mg comprimidos recubiertos con película EFG, Atorvastatina NORMON 20 mg comprimidos recubiertos con película EFG, Simvastatina NORMON 40 mg comprimidos recubiertos con película EFG, Atorvastatina NORMON 40 mg comprimidos recubiertos con película EFG, Atorvastatina NORMON 10 mg comprimidos recubiertos con película EFG, Atorvastatina Normon 60 mg comprimidos recubiertos con película, Simvastatina NORMON 20 mg comprimidos recubiertos con película EFG

    The George Institute

    Spontaneous lobar ICH

    phase 3 small molecule active

    1 trial

  20. Soliris 300 mg concentrate for solution for infusion, Pozelimab, Cemdisiran, Ultomiris 300 mg/3 mL concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Paroxysmal nocturnal haemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  21. Ultomiris 300 mg/30 mL concentrate for solution for infusion, Soliris 300 mg concentrate for solution for infusion, ALXN 2040

    Alexion Europe SAS

    Patients with Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule active

    1 trial

  22. rVA576

    Akari Therapeutics Plc

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule terminated

    1 trial

  23. rVA576

    Akari Therapeutics Plc

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule completed

    1 trial

  24. ALN-CC5

    Alnylam Netherlands B.V.

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources